{"id":"W2965009353","doi":"10.1016/j.jaad.2019.07.074","title":"Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study","year":2019,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":256,"is_retracted":false,"has_abstract":true,"ca_institutions":"Innovaderm (Canada)","funders":"Genentech; LEO Pharma; Coherus Biosciences; Kaken Pharmaceutical; Asana Biosciences; Kiniksa Pharmaceuticals; Aimmune Therapeutics; Janssen Biotech; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; Valeant Pharmaceuticals International; Galderma; UCB; Regeneron Pharmaceuticals; Sun Pharma; Dermira; Therakos; Taiho Pharmaceutical; F. Hoffmann-La Roche; Glenmark Pharmaceuticals; AbbVie; Novartis; Celgene; Boehringer Ingelheim; Amgen; Sanofi Genzyme; Merck Sharp and Dohme; 3M; Roche; University of Pennsylvania; Kyowa Hakko Kirin; Sanofi; Merck; GlaxoSmithKline; Incyte; Pfizer; Allergan; AstraZeneca; Eli Lilly and Company","keywords":"Dupilumab; Medicine; Atopic dermatitis; Open label; Dermatology; Term (time); Adverse effect; Internal medicine","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000172138,0.0002002846,0.001371254,0.0003440338,0.00004631717,0.00001236376,0.0003989879,0.00008374408,0.00002419882],"category_scores_gemma":[0.00012993,0.0001295353,0.00005407032,0.0004073929,0.0002079953,0.00020453,0.0002364158,0.000540946,0.000004859622],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000558384,"about_ca_system_score_gemma":0.0001156503,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001373599,"about_ca_topic_score_gemma":0.00001572488,"domain_scores_codex":[0.9978384,0.00046027,0.000906336,0.0002331676,0.0002839015,0.0002779744],"domain_scores_gemma":[0.9985204,0.000207919,0.0008143114,0.0002135726,0.00008160569,0.0001621292],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01087758,0.003597093,0.9814786,0.00005887777,0.00017494,0.0003036515,0.0005299074,0.00005962242,0.00007153784,0.00000582797,0.0003198594,0.002522484],"study_design_scores_gemma":[0.05141138,0.0009410851,0.9442772,0.000357357,0.0001345135,0.002307349,0.0001636598,0.000107919,0.0001202772,0.00002295457,0.00002718588,0.0001290679],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928102,0.0002425396,0.00001124808,0.005463338,0.00005143288,0.001364535,0.000006448429,0.000004440108,0.0000458007],"genre_scores_gemma":[0.9965158,0.00005555822,0.0001661886,0.003198286,0.000008245497,0.000006930888,0.000001514241,0.0000172049,0.0000303191],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0405338,"threshold_uncertainty_score":0.5282296,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01646187673682043,"score_gpt":0.3249315183708346,"score_spread":0.3084696416340141,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}